FDA Pharmaceutical and Medical Device Books
Published: April 2012 | Pages: 124 | Price: $377 | ISBN: 978-1-60428-029-6
This new-and-revised collection from FDAnews draws on the experience of thousands of trial sites worldwide. They’re compiled from stories that first appeared in Clinical Trials Advisor newsletter, the industry’s trusted source of management and compliance guidance.
Published: June 2012 | Pages: 74 | Price: $377 | ISBN: 978-1-60428-061-6
The FDA adopted ICH Q10 for good reason: The lifecycle approach to drug GMP promises to improve quality across the board. A pity, then, that most drugmakers didn’t use a lifecycle approach when ICH Q10 made its bow ... and didn’t have a clue as to how to begin. Many still don’t. But worry not — help is at hand.
Published: June 2009 | Pages: 48 | Price: $357 | ISBN: 978-1-60004-054-2
A Sponsor’s Guide to Auditing IRBs: Detecting Deficiencies and Ensuring Best Practices is the one step-by-step management report that gives you the tools you need to determine if your IRBs are complying with federal regulations. With Congress threatening legislation that will fortify FDA and HHS oversight, you’ll need to act fast. Order your copy now to discover how to avoid an IRB compliance disaster once and for all.
Published: December 2007 | Pages: 139 | Price: $337 | ISBN: 978-1-60004-178-5
From FDAnews — Adverse Event Compliance in Device and Diagnostics Clinical Trials. Find clear, concise guidelines on adverse event reporting — specifically for device and diagnostics trials. Make sense of all the whats, whens and hows surrounding adverse event reporting. Once an adverse event happens, it’s too late: you have just 10 working days to submit to the IRB and 10 days after that to get results to the FDA. Stay in control, even when unanticipated events happen.
Published: February 2011 | Pages: 27 | Price: $327 | ISBN: 978-1-60004-228-7
There’s no doubt that these new requirements will increase the regulatory burden on drug and biologics trial sponsors and investigators already laboring under a heavy load. That’s why the new special report Adverse Event Reporting for Drug and Biologics Trials is essential for busy executives involved in clinical trials and regulatory affairs.
Published: May 2011 | Pages: 36 | Price: $377 | ISBN: 978-1-60004-239-3
This management report from FDAnews provides drugmakers and suppliers with a thorough overview of the EU’s risk management approach.
Published: February 2012 | Pages: 214 | Price: $377 | ISBN: 978-1-60428-018-0
Before you begin to modify an existing trial, this new report from FDAnews maps out the specific planning and preparation it takes to win FDA approval for adaptive clinical trials. By combining a concise overview with a detailed analysis of FDA’s preferences, this one report advises you on everything thing from the best trial model to use to the best way to avoid technical problems with final data analysis.
Published: April 2013 | Pages: 189 | Price: $397 | ISBN: 978-1-60428-108-8
CAPA keeps confounding medical device manufacturers. For two years running, CAPA has spawned more device warning letters than any other regulatory issue. And 2013 is shaping up as just as bad as 2011-12 — or maybe even worse. CAPA’s reporting and recordkeeping demands are major headaches.How does the FDA define ‘well-written report’? How can devicemakers best justify the risk analysis used to support CAPA implementation decisions? How can devicemakers best evaluate CAPA filing systems for FDA compliance? This new one-of-a-kind report from FDAnews has the answers — and more …
Published: February 2007 | Pages: 143 | Price: $395 | ISBN: 1-60004-136-1
Glean real-world insight with examples of working change control systems, specifically targeted to the unique needs of drug and biologic manufacturers, with this new management report. Don't delay, order this distinctive management report filled with common sense procedures on change control that you can use today.
Published: March 2007 | Pages: 112 | Price: $395 | ISBN: 1-60004-138-8
Don't miss out! Successfully sidestep the delayed approvals, lost product batches and plummeting profits that can result from change control failures with this comprehensive report. Change Control: Best Practices for FDA-Compliant Medical Device Manufacturers.
Published: January 2011 | Pages: 74 | Price: $1,500
China Pharmaceutical Regulatory Report 2011, the research report that gives you a thorough understanding of the Chinese regulatory structure governing the drug industry. You’ll get a complete discussion of the laws and regulations that govern the testing, product registration, manufacturing, importing, marketing and sales of pharmaceuticals. All this and more from Ames Gross and John Minot of Pacific Bridge Medical, the consulting firm that has provided hundreds of companies with regulatory information and business strategies to develop Asian markets.
Published: April 2012 | Pages: 155 | Price: $750
In this clear yet comprehensive new resource developed by Access China Management Consulting Ltd., FDAnews provides an English-language guide that makes it easier to navigate the Chinese medical device registration system.
Published: April 2012 | Pages: 231 | Price: $1,495
With a new resource developed by Access China Management Consulting Ltd., FDAnews offers non-Chinese companies the know-how to move into China’s lucrative pharmaceuticals market without giving up their intellectual property rights.
Published: November 2009 | Pages: 27 | Price: $377 | ISBN: 978-1-60004-079-5
Cleaning Validation: Strategies for Compliance goes beyond the regulations and digs into the real-life world of cleaning validation. Tips to create an effective master plan ... appropriate SOPs ... auditing for compliance ... practical solutions to troublesome cleaning validation challenges ... this timely volume help keep the FDA at bay, boost production efficiency, and fatten your bottom line.